Comparison studies of tacrine and bis(7)-tacrine on the suppression of scopolamine-induced behavioral changes and inhibition of acetylcholinesterase in mice

Pharmacology

Volumn 83, Issue 5, 2009, Pages 294-300

  Pan, Si Yuan ^a   Yu, Zhi Ling ^b   Xiang, Chun Jing ^a   Dong, Hang ^b   Fang, Hai Yan ^a   Ko, Kam Ming ^c  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Acetylcholinesterase activity; Bis(7) tacrine; Cognitive function; Locomotor activity; Open field memory; Passive avoidance response; Scopolamine; Tacrine

Indexed keywords

ACETYLCHOLINESTERASE; BIS(7) TACRINE; SCOPOLAMINE; TACRINE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; MALE; MEMORY; MOTOR DYSFUNCTION; MOUSE; NEUROMODULATION; NONHUMAN; OPEN FIELD BEHAVIOR; PASSIVE AVOIDANCE; PRIORITY JOURNAL;

ACETYLCHOLINESTERASE; ANIMALS; AVOIDANCE LEARNING; BRAIN; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; SCOPOLAMINE; TACRINE;

EID: 64149094823     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000211668     Document Type: Article

References (25)

1. Samanta MK, Wilson B, Santhi K, Kumar KP, Suresh B: Alzheimer disease and its management: a review. Am J Ther 2006;13: 516-526.
2. Souchay C: Metamemory in Alzheimer's disease. Cortex 2007;43:987-1003.
3. Ertekin-Taner N: Genetics of Alzheimer's disease: a centennial review. Neurol Clin 2007;25:611-617
4. Musial A, Bajda M, Malawska B: Recent developments in cholinesterase inhibitors for Alzheimer's disease treatment. Curr Med Chem 2007;14:2654-2679.
5. Brousseau G, Rourke BP, Burke B: Acetyl-cholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement. Exp Clin Psychopharmacol 2007;15:546-554.
6. Mesulam M, Wicklund A, Johnson N, Rogalski E, Léger GC, Rademaker A, Weintraub S, Bigio EH: Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008;63:709-719.
7. Cuello AC, Bruno MA, Bell KF: NGF-cholinergic dependency in brain aging, MCI and Alzheimer's disease. Curr Alzheimer Res 2007;4:351-358.
8. Cacabelos R: Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Methods Find Exp Clin Pharmacol 2007; 29(suppl A):1-91.
9. Swerdlow RH: Pathogenesis of Alzheimer's disease. Clin Inter v Aging 2007;2:347-359.
10. Arrieta JL, Artalejo FR: Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature. Age Ageing 1998;27:161-179.
11. Evans JG, Wilcock G, Birks J: Evidence-based pharmacotherapy of Alzheimer's disease. Int J Neuropsychopharmacol 2004;7: 351-369.
12. Benjamin B, Burns A: Donepezil for Alzheimer's disease. Expert Rev Neurother 2007;7:1243-1249.
13. Pang YP, Quiram P, Jelacic T, Hong F, Brimi-join S: Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. J Biol Chem 1996;271: 23646-23649.
14. Wang H, Carlier PR, Ho WL, Wu DC, Lee NT, Li CP, Pang YP, Han YF: Effects of bis(7)-tacrine, a novel anti-Alzheimer's agent, on rat brain AChE. Neuroreport 1999;10:789-793.
15. Wang H, Carlier PR, Ho WL, Lee NT, Pang YP, Han YF: Attenuation of scopolamine-in-duced deficits in navigational memory performance in rats by bis(7)-tacrine, a novel dimeric ACh E inhibitor. Acta Phar macol Sin 1999;20:211-217.
16. Liu J, Ho W, Lee NT, Carlier PR, Pang Y, Han Y: Bis(7)-tacrine, a novel acetylcholinesterase inhibitor, reverses AF64A-induced deficits in navigational memory in rats. Neurosci Lett 2000;282:165-168.
17. Pan SY, Han YF, Yu ZL, Yang R, Dong H, Ko KM: Evaluation of acute tacrine treatment on passive-avoidance response, open-field behavior, and toxicity in 17- and 30-day-old mice. Pharmacol Biochem Behav 2006;85: 50-56.
18. Pan SY, Yu ZL, Dong H, Lee NT, Wang H, Fong WF, Han YF, Ko KM: Evaluation of acute bis(7)-tacrine treatment on behavioral functions in 17-day-old and 30-day-old mice, with attention to drug toxicity. Pharmacol Biochem Behav 2007;86:778-783.
19. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 1976;72:248-254.
20. Mehta H, Haobam R, Usha R, Mohanakumar KP: Evidence for the involvement of central serotonergic mechanisms in cholinergic tremor induced by tacrine in Balb/c mice. Behav Bra in Res 2005;163:227-236.
21. Pan SY: Circadian effects of scopolamine on memory, exploratory behavior, and muscarinic receptors in mouse brain. Acta Pharmacol Sin 1992;13:323-326.
22. Pan SY: Features of memory on novel situation and avoidance response: evidence from comparison between open-field behavior and step-through task. Acta Pharmacol Sin 1995;16:125-129.
23. Pan SY, Han YF, Xu QP, Liu MY, Ma HZ, Ding WJ, Zhu RL: Belladonna alkaloids-induced behavioral changes and amnesia on open-field and step-through in 18-, 28- and 38-day-old mice. Acta Pharmacol Sin 1998; 19:112-116.
24. Pan SY, Han YF: Comparison of the inhibitory efficacy of four belladonna drugs on gastrointestinal movement and cognitive function in food-deprived mice. Pharmacology 2004;72:184-189.
25. Itoh A, Nitta A, Katono Y, Usui M, Naruhashi K, Iida R, Hasegawa T, Nabeshima T: Effects of metrifonate on memory impairment and cholinergic dysfunction in rats. Eur J Pharmacol 1997;322:11-19.